Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | S100A4 | P26447 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | PTPRF | P10586 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628570 | 0.71 | CYP19A1 (0.43) | MEN1KMT2APOLBCYP19A1TSHR | |
| SCHEMBL6568999 | 0.69 | HTR2A (0.34) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL15217970 | 0.69 | MAOA (0.32) | CYP1A2ALDH1A1 | |
| SCHEMBL5582475 | 0.68 | — | — | |
| SCHEMBL15874621 | 0.67 | CYP2A6 (0.39) | PTPN1MAPTCYP19A1PARP1 | |
| SCHEMBL15874619 | 0.67 | CYP2A6 (0.39) | PTPN1MAPTCYP19A1PARP1 | |
| SCHEMBL2356347 | 0.65 | MAPT (0.33) | MAPT | |
| SCHEMBL2241169 | 0.65 | MAPT (0.33) | MAPT | |
| SCHEMBL901386 | 0.65 | MAPT (0.33) | MAPT | |
| SCHEMBL11301311 | 0.65 | TP53 (0.36) | TP53HTR2BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | claimed |
| EP-1819656-A2 | SYNTHESIS OF 1,5-DISTRIBUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2007081895-A2 | PREPARATION OF SUBSTITUTED 2-HYDROXYGIBBA-1(10A), 2, 4, 4B-TETRAEN-6-ONES | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | claimed |
| WO-2006050399-A2 | SYNTHESIS OF 1,5-DISUBSTITUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1827421-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2773643-A1 | PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME | Afraxis Holdings, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2773642-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | Afraxis Holdings, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013067434-A1 | PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067423-A1 | PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AFRAXIS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2453896-A2 | METHODS FOR TREATING SCHIZOPHRENIA | Afraxis, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-1943224-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2004026887-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1339683-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003015761-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002041835-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-4731471-A | (5,6-dichloro-3-oxo-2,3,9,9a-tetrahydrofluoren-7-yl)-alkanoic acids and alkanimidamides bearing novel functional 9a-substituents | MERCK & CO., INC. (US) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | PTPN1 2246/4885S100A4 2610/4885MEN1 3259/4885 |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | ESR1, GPER1, CYP19A1 | PTPN1 4519/4885S100A4 4728/4885MEN1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.